Changing environment leads PPD to set up in Japan
This article was originally published in Scrip
Executive Summary
The US contract research company PPD has established a new direct presence in Japan. An office in Tokyo will provide Phase II to postmarketing clinical trial management services in response to growing demand in East Asia. There had been a significant increase in multinational studies including sites in Japan, the company said. Contrary to its past image as a slow and expensive place for clinical work, PPD's CEO Fred Eshelman said: "Japan offers competitive timelines for site start-up and patient enrolment, and the government is making major improvements to streamline drug development." These include a project to set up a national network of trial centres.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.